Sirona Biochem (Seite 1271)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 19.04.24 13:21:16 von
neuester Beitrag 19.04.24 13:21:16 von
Beiträge: 31.013
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 89
Gesamt: 5.398.716
Gesamt: 5.398.716
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0405
EUR
-6,90 %
-0,0030 EUR
Letzter Kurs 10:00:25 Tradegate
Neuigkeiten
08.04.24 · globenewswire  |
05.04.24 · globenewswire |
28.03.24 · globenewswire |
13.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0000 | +67,36 | |
| 6,2200 | +33,97 | |
| 1,4800 | +33,82 | |
| 10,625 | +26,94 | |
| 2,9200 | +18,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,5500 | -18,13 | |
| 3,3500 | -18,89 | |
| 5,6050 | -29,85 | |
| 0,6021 | -35,26 | |
| 3,9400 | -43,31 |
Beitrag zu dieser Diskussion schreiben
FeedbackSirona Biochem Announces Grant of Stock Options
Sirona Biochem Announces Grant of Stock OptionsVANCOUVER, Jan. 21, 2020
VANCOUVER, Jan. 21, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)(US-OTC: SRBCF)("Sirona" or the "Company") announces that it has granted an aggregate of 6,800,000 incentive stock options to management, independent directors and consultants of the Company. The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years. The options have been granted under the terms of the Company's stock option plan.
Sirona Biochem Corp. (CNW Group/Sirona Biochem Corp.)
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/21/c1…
Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.comCopyright CNW Group 2020
Canada Newswire
January 21, 2020 - 12:01 AM PST
Healthcare | Biotechnology | Biotechnology | Sirona Biochem Corp.
https://stockhouse.com/news/press-releases/2020/01/21/sirona…
Schaut unter Finanznachrichten.de !
wie kommt ihr auf us-dollar? sirona sitzt in canada, alle angaben sind entsprechend in canadischen dollar. war nie anders.
Antwort auf Beitrag Nr.: 62.436.315 von pater-noster am 21.01.20 10:20:36...wo steht das genau, welche Währung gemeint ist ?
USD 0,45 entspricht etwa CAD 0,57 oder EUR 0,3975
Trading Spotlight
Man hat das ‚Große‘ vor Augen und lässt sich das dementsprechend gebührend vergüten. 👍
Antwort auf Beitrag Nr.: 62.436.315 von pater-noster am 21.01.20 10:20:36...
The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years.
...
The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years.
...
Antwort auf Beitrag Nr.: 62.436.252 von pennytrade am 21.01.20 10:16:04ja, bitte genau lesen. 45 cent (canadische cent). das entspricht exakt dem gestrigen schlusskurs in canada. das umrechnen in euro-cent kannst du dir sparen.
Antwort auf Beitrag Nr.: 62.435.961 von Hydro_11 am 21.01.20 09:49:57Lasset die Spiele beginnen🙃
Antwort auf Beitrag Nr.: 62.436.201 von pater-noster am 21.01.20 10:11:58bitte genau lesen, 0,45 USD = 40,57 Cent
Durchsuchen
